Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results

Eli Lilly reported Q1 FY2026 revenue of $19.8B (+56% YoY) and non-GAAP EPS of $8.55 (+156% YoY), driven by Zepbound and Mounjaro at $12.8B combined. The company guided to as much as $85B in annual revenue and $37 in EPS, while analysts expect EPS to rise this year by +21.7%. Shares were already up ~12% YTD, and the article highlights renewed “Big Money” institutional inflows and outlier inflow signals, pointing to continued strong demand.

Analysis

LLY is transitioning from a pure growth compounder to a reimbursement-and-capacity story. The market is likely underestimating how much of the next leg depends on execution quality: if coverage expands smoothly, the company can convert demand into durable share gains; if not, the headline becomes a near-term multiple event rather than a lasting earnings re-rate. The biggest second-order winner is LLY’s own U.S. commercial moat versus other obesity/diabetes players, especially NVO and smaller entrants that still face a tougher formulary battle.

The main risk is that access expansion does not translate linearly into net revenue. Payers can respond with tighter utilization controls, higher rebate demands, and narrower channel access, which would blunt the upside while still forcing Lilly to spend to defend share. In the next 1-3 months, the stock will trade on how quickly the market believes incremental patients can be onboarded; over 6-18 months, the question is whether the franchise sustains premium growth without margin erosion or a deceleration in script momentum.

Consensus is probably too comfortable treating institutional buying as confirmation. Flow can amplify a momentum move after earnings, but it does not solve valuation or saturation risk. The contrarian view is that a large part of the obesity opportunity may be pulled forward into the stock already, so any disappointment in coverage breadth, discontinuation rates, or manufacturing cadence could trigger a sharp relative derating even if fundamentals remain strong.

Key Decisions for Investors

• Accumulate LLY only on pullbacks rather than chasing strength; use a 3-6 month horizon and require confirmation that access expands without a gross-margin reset. Falsifier: a narrower-than-expected Medicare implementation or a guide-down in profitability.
• Pair trade: long LLY / short NVO for a 1-3 month relative-value expression on U.S. commercialization and formulary execution. This works best if LLY keeps taking share while NVO faces slower access gains; cover if relative performance stalls after CMS details.
• Prefer call spreads over outright long calls if entering after a post-earnings run, to reduce implied-volatility bleed. Structure for 3-6 months out; the trade is only attractive if the stock can extend on continued estimate revisions, not just momentum.
• Set a watch alert for any CMS or payer language that narrows obesity coverage through prior auth, step therapy, or site-of-care rules. That would likely cap upside quickly and is the cleanest signal to reduce exposure.